Synapse - Samuel Funt

Search Within

Samuel Aaron Funt

Results (143)

Adjuvant chemotherapy with etoposide plus cisplatin for patients with pathologic stage II nonseminomatous germ cell tumors

Journal Article

McHugh, D. J.; Funt, S. A.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Cancer susceptibility mutations in patients with urothelial malignancies

Journal Article

Carlo, M. I.; Ravichandran, V.; Srinavasan, P.; Bandlamudi, C.; Kemel, Y.; Ceyhan-Birsoy, O.; Mukherjee, S.; Mandelker, D.; Chaim, J.; Knezevic, A.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)

Meeting Abstract

Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)

Meeting Abstract

Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J. S.; Patil, S.; Reuter, V. E.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Milowsky, M. I.; Appleman, L. J.; Dorff, T. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT)

Meeting Abstract

Wong, N. C.; Dason, S.; Dean, L. W.; Isharwal, S.; Donoghue, M.; Jia, L.; Joseph, G.; Tap, W. D.; Funt, S. A.; McHugh, D. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?

Meeting Abstract

Mota, J. M. S. C.; Teo, M. Y.; Li, H.; Balar, A. V.; Milowsky, M. I.; Funt, S. A.; Lee, C. H.; Regazzi, A. M.; Berger, M. F.; Solit, D. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)

Meeting Abstract

Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT)

Meeting Abstract

Dean, L. W.; Wong, N. C.; Dason, S.; Isharwal, S.; Donoghue, M.; Jia, L.; Tap, W. D.; Joseph, G.; Funt, S. A.; McHugh, D. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration

Meeting Abstract

Funt, S. A.; Solovyov, A.; Faltas, B. M.; Iyer, G.; Boyd, M. E.; Cipolla, C. K.; Regazzi, A. M.; Teo, M. Y.; Lee, C. H.; Al-Ahmadie, H.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save